Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...
Launched in January, TrumpRx.gov is part of a series of most-favored-nation deals struck between the Trump administration and ...
War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive ...
Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...
Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...
In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to ...
Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical ...
Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling ...
PE: How does patient adherence impact both the science and finance of clinical trials? Li: Obviously, adherence is a key ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results